These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26826416)

  • 41. [Diagnosis, prognosis, and prediction of non-small cell lung cancer. Importance of morphology, immunohistochemistry and molecular pathology].
    Warth A
    Pathologe; 2015 Nov; 36 Suppl 2():194-200. PubMed ID: 26391251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
    Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
    Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
    Yang JW; Choi YL
    Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Applications and limitations of immunohistochemical expression of "Napsin-A" in distinguishing lung adenocarcinoma from adenocarcinomas of other organs.
    Kadivar M; Boozari B
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):191-5. PubMed ID: 22914608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ALK-rearranged adenosquamous lung cancer presenting as squamous cell carcinoma: a potential challenge to histologic type triaging of NSCLC biopsies for molecular studies.
    Dragnev KH; Gehr G; Memoli VA; Tafe LJ
    Clin Lung Cancer; 2014 May; 15(3):e37-40. PubMed ID: 24524823
    [No Abstract]   [Full Text] [Related]  

  • 46. Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.
    Oshita F; Kasajima R; Miyagi Y
    J Exp Ther Oncol; 2016 Jul; 11(3):189-194. PubMed ID: 28471124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
    Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
    Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protein correlates of molecular alterations in lung adenocarcinoma: Immunohistochemistry as a surrogate for molecular analysis.
    Sholl LM
    Semin Diagn Pathol; 2015 Sep; 32(5):325-33. PubMed ID: 25753527
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
    Guibert N; Barlesi F; Descourt R; Léna H; Besse B; Beau-Faller M; Mosser J; Pichon E; Merlio JP; Ouafik L; Guichard F; Mastroianni B; Moreau L; Wdowik A; Sabourin JC; Lemoine A; Missy P; Langlais A; Moro-Sibilot D; Mazières J
    J Thorac Oncol; 2017 Jun; 12(6):963-973. PubMed ID: 28189832
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adenosquamous carcinoma of the lung diagnosed by cytology?: a diagnostic dilemma.
    Shelton DA; Rana DN; Holbrook M; Taylor P; Bailey S
    Diagn Cytopathol; 2012 Sep; 40(9):830-3. PubMed ID: 21416646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases.
    Fishback NF; Travis WD; Moran CA; Guinee DG; McCarthy WF; Koss MN
    Cancer; 1994 Jun; 73(12):2936-45. PubMed ID: 8199991
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidermal growth factor receptor as an adverse survival predictor in squamous cell carcinoma of the penis.
    Silva Amancio AM; Cunha IW; Neves JI; Quetz JD; Carraro DM; Rocha RM; Zequi SC; Cubilla AL; da Fonseca FP; Lopes A; Cunha MD; Lima MV; Vassallo J; Guimarães GC; Soares FA
    Hum Pathol; 2017 Mar; 61():97-104. PubMed ID: 27864120
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge.
    Pelosi G; Fabbri A; Papotti M; Rossi G; Cavazza A; Righi L; Tamborini E; Perrone F; Settanni G; Busico A; Testi MA; Maisonneuve P; De Braud F; Garassino M; Valeri B; Sonzogni A; Pastorino U
    J Thorac Oncol; 2015 Nov; 10(11):1560-9. PubMed ID: 26317919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 58. p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis.
    Vogt AP; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2014 May; 42(5):453-8. PubMed ID: 24166777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
    J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Case-control Study Supporting the Use of Liquid Biopsy in the Targeted Therapy for Lung Cancer.
    Dai LJ; Wang C; Ding ZY
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1761-1766. PubMed ID: 30049184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.